Nuvalent sees success for its second genetically targeted lung cancer drug Data suggest neladalkib can help patients with ALK+ cancer whose tumors returned

https://www.statnews.com/2025/11/17/nuvalent-alk-lung-cancer-drug-neladalkib-succeeds/